EPO rDNA Stada - Biotech, Pharma and Life Science Channel
PubMed Articles
Longidorus aetnaeus Roca, Lamberti, Agostinelli & Vinciguerra, 1986 is reported for the first time from Iran and Ajaria (Georgia). Morphological and morphometric data are provided for two Iranian and...
A population of Xiphinema macroacanthum Lamberti, Roca & Agostinelli, 1989 originating from olive orchards in Brindisi, Italy and containing both adults and all juvenile stages, is described and illus...
BACKGROUND AND PURPOSE: This study investigated the prognostic role of tumor cell expression of erythropoietin (EPO) and its receptor (EPO-R) in patients with locally advanced squamous cell carcinoma...
Hypoxia inducible factor (HIF) and 5'-AMP-activated protein kinase are often activated under similar physiological conditions. Constitutive androstane receptor (CAR) translocates into the nucleus in a...
Microcystins (MCs) cause normocytic anemia in patients in a hemodialysis unit in Caruaru, Brazil in 1996, but the underlying mechanisms are still unclear. In the present study, Balb/c mice were intrap...
Microsporum fulvum, an Ignored Pathogenic Dermatophyte: A New Clinical Isolation from Iran.
Misidentifying with Microsporum gypseum has for a long time been accounted for less prevalence of the geophilic species, Microsporum fulvum in human dermatophytosis. We describe a new case of infectio...
Changes in DNA methylation patterns and repetitive sequences in blood lymphocytes of aged horses.
It is known that aged organisms have modified epigenomes. Epigenetic modifications, such as changes in global and locus-specific DNA methylation, and histone modifications are suspected to play an imp...
Erythropoietin (EPO) was hypothesized to mitigate reperfusion injury, in part via mobilization of endothelial progenitor cells (EPCs). The REVEAL trial found no reduction in infarct size with a single...
Erythropoietin (EPO) is the main hormone that regulates erythropoiesis. Beyond its well-known hematopoietic action, EPO has diverse cellular effects in non-hematopoietic tissues. It has been shown to...
Although larvae of the genus Trichinella are the most common parasite species detected in vertebrate muscles using artificial digestion, nematode larvae belonging to other genera are sometimes detecte...
News Articles
DGAP-Stimmrechte: STADA Arzneimittel AG (deutsch)
STADA Arzneimittel AG: Veröffentlichung gemäß § 26 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung STADA Arzneimittel AG 23.05.2013 13:31 Veröffentlichung einer Stimmrechtsmitteilung, über...
NPS Pharmaceuticals to Present at Deutsche Bank Health Care Conference
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Deutsche Bank Securities 38th Annual Health Care Conference in Boston on Wednesday, May 29, 2013 at 8:00 a.m. ET. The...
Stada: Deutsche Bank zeigt Interesse
Bei Stada gibt es eine Veränderung in der Investorenstruktur. Ein Aktionär überschreitet am 16. Mai die meldepflichtige Schwelle von 3 Prozent. Dabei handelt es sich um die DWS Investment aus Frank...
STADA Arzneimittel AG: Neues 52-Wochenhoch (34.23 Euro, Long)
Unsere Produkte: Wave-XXL-Call DX4Z2ZWave-XXL-Put DX5QT9STADA Arzneimittel AG (WKN: 725180)Signal vom 21.05.2013 11:44:29 bei 34.23 EuroNeues 52-WochenhochFür spekulativ orientierte Anleger, die vo.....
STADA Arzneimittel AG: Neues 26-Wochenhoch (34.23 Euro, Long)
Unsere Produkte: Wave-XXL-Call DX4Z2ZWave-XXL-Put DX5QT9STADA Arzneimittel AG (WKN: 725180)Signal vom 21.05.2013 11:44:29 bei 34.23 EuroNeues 26-WochenhochFür spekulativ orientierte Anleger, die vo.....
STADA Arzneimittel AG: Neues 13-Wochenhoch (34.23 Euro, Long)
Unsere Produkte: Wave-XXL-Call DX4Z2ZWave-XXL-Put DX5QT9STADA Arzneimittel AG (WKN: 725180)Signal vom 21.05.2013 11:44:29 bei 34.23 EuroNeues 13-WochenhochFür spekulativ orientierte Anleger, die vo.....
Deutsche Bank lanciert 5,00% Aktienanleihe auf STADA
Westerburg - Die Deutsche Bank bietet eine Aktienanleihe (ISIN DE000DB2GNP7/ WKN DB2GNP) auf STADA (ISIN DE0007251803/ WKN 725180) zur Zeichnung an.Die Anleihe kann noch bis zum 28. Mai 2013 gezeic...
STADA: Gute Zahlen und positive Analystenstimmen beflügeln Kurs
STADA hat im ersten Quartal Umsatz und Ergebnis gesteigert. Mit den guten Zahlen im Rücken ist die MDAX-Aktie zuletzt auf ein neues Jahreshoch gestiegen. Positive Analystenstimmen stützen den Kurs ....
Global Biosimilar Market Report 2013
Visiongain published a new report on the global biosimilar market in 2013 and says the market size will reach $2.45 B, or approximately 20% higher than last year. Biosimilars now account for about 2%...
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today...
Events
None
Companies
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support...
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support...
NPS Pharmaceuticals is engaged in the discovery, development and commercialization of therapeutic small molecules and recombinant proteins to treat bone and mineral, gastrointestinal and central nervo...
NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registratio...
Clinical Trials
Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant Recipients
Correction of anaemia in renal transplant recipients by parenteral application of recombinant erythropoietin and if necessary iron will improve large artery function (endothelial function...
PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation
Randomized, double blind, placebo controlled, prospective trial investigating the effect of erythropoietin in renal transplantation. The investigators postulate that erythropoietin reduc...
Erythropoietin in Acute Myocardial Infarction
Erythropoietin (EPO) is a naturally occuring hormone which regulates the body's response to lack of oxygen and controls the number of red cells in the blood. Recent studies in animals have...
Erythropoietin Therapy for Subarachnoid Hemorrhage
ABSTRACT: Delayed ischemic deficits (DID) and strokes caused by low cerebral blood flow (CBF) are major sources of poor outcome following aneurysmal subarachnoid hemorrhage (SAH). DID are...
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
Objectives: Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk MDS. Secondary: To evaluate response duration, survival and side effects of the treatment.
Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial
Full Title: A Randomized Controlled Trial of Procrit for the Prevention of Acute Renal Failure in Patients Receiving Intravenous Contrast Primary Objective: To evaluate the efficacy of a...
Study of the Relationship Between rHuEPO Dose, Serum ADPN, and Mortality in Patients Beginning HD
Responsiveness of recombinant human erythropoietin (rHuEPO) is known to be related with body fatness in hemodialysis (HD) patients. Adiponectin (ADPN) is inversely associated with body fat...
Dynepo Infrequent Dosing Study
The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as m...
Hepcidin in Anemic Chronic Heart Failure (CHF) Patients
Background: Anemia in chronic heart failure (CHF) is directly linked to increased mortality and reduced exercise capacity. The pathomechanism for the development of anemia in CHF is not...
Does Erythropoietin Improve Outcome in Very Preterm Infants?
HYPOTHESIS Early administration of human erythropoietin (EPO) in very preterm infants reduces perinatal injury to the brain (retina), lung and gut and improves neurodevelopmental outcome a...
Videos
Medical and Biotech [MESH] Definitions
Receptors, Eph Family
A large family of receptor protein-tyrosine kinases that are structurally-related. The name of this family of proteins derives from original protein Eph (now called the EPHA1 RECEPTOR), which was named after the cell line it was first discovered in: Erythropoietin-Producing human Hepatocellular carcinoma cell line. Members of this family have been implicated in regulation of cell-cell interactions involved in nervous system patterning and development.
Receptor, Epha1
The founding member of the EPH FAMILY RECEPTORS. It was first cloned from an erythropoietin-producing human hepatocellular carcinoma cell line and is highly conserved among many mammalian species. Overproduction of the EphA1 receptor is associated with tumors and tumor cells of epithelial origin. It is also expressed at high levels in LIVER; LUNG; and KIDNEY; which is in contrast to many other members of the Eph receptor that are found primarily in tissues of the nervous system.
Actinobacteria
Class of BACTERIA with diverse morphological properties. Strains of Actinobacteria show greater than 80% 16S rDNA/rRNA sequence similarity among each other and also the presence of certain signature nucleotides. (Stackebrandt E. et al, Int. J. Syst. Bacteriol. (1997) 47:479-491)
Janus Kinase 2
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
Erythroid Precursor Cells
The cells in the erythroid series derived from MYELOID PROGENITOR CELLS or from the bi-potential MEGAKARYOCYTE-ERYTHROID PROGENITOR CELLS which eventually give rise to mature RED BLOOD CELLS. The erythroid progenitor cells develop in two phases: erythroid burst-forming units (BFU-E) followed by erythroid colony-forming units (CFU-E); BFU-E differentiate into CFU-E on stimulation by ERYTHROPOIETIN, and then further differentiate into ERYTHROBLASTS when stimulated by other factors.
